Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P733 | DOI: 10.1530/endoabs.35.P733

ECE2014 Poster Presentations Neuroendocrinology (27 abstracts)

Prolactinemia and clinical outcome following second generation antipsychotics in early onset schizophrenia

Iuliana Dobrescu 1, , Carmen Trutescu 1 , Liana Kobylinska 1 , Florina Rad 1, , Cristina Petrescu-Ghenea 1 , Gianina Cristina Anghel 1, & Ilinca Mihailescu 1


1Child and Adolescent Psychiatry Department, Professor Dr. Al. Obregia Clinical Psychiatry Hospital, Bucharest, Romania; 2Child and Adolescent Psychiatry Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.


Introduction: As antipsychotic drugs specifically block the D2 receptors, they induce a certain level of prolactin increase, dependent on the time it takes to dissociate from receptors. A recent review (Besnard et al, 2013) mentions that 18% of men and 47% of women treated with antipsychotics for severe mental illness had an increased prolactin level. Even if the long term effects of hyperprolactinemia can be severe, including low bone density, amenorrhea, breast and prostate cancer, new evidence suggests that the increase of prolactin within a certain range under antipsychotic treatment might correlate with a positive evolution in schizophrenic patients.

Methods: Fifteen adolescents aged 14–17, diagnosed with early-onset and very-early-onset schizophrenia according to DSM-IV criteria and KIDDIE-SADS scales were included in the study. They were treated with risperidone 2–4 mg/day. The values of serum prolactine and the PANSS, CGI-S and CGAS scores were followed at baseline, 3 months, 6 months and 1 year.

Results: None of the males included in the lot developed symptoms of hyperprolactinemia; part of the included females developed amenorrhea and one had galactorrhea. Serum prolactin levels increased at 3 months, correlated with a decrease in the PANSS score, and then decreased and stabilized to a level higher than baseline at 6 months and 1 year, with no significant differences in the PANSS scores within this time frame. The rest of the results are still to be analysed.

Conclusions: The small number of patients is a limitation - studies on bigger populations are necessary and that is why we consider this as a starting point for future research in order to find predictive factors in schizophrenia approach.

Article tools

My recent searches

No recent searches.